Nuzenio

Mediar Therapeutics

Mediar Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 9 latest news signals 7 publisher sources 100/100 entity strength

Latest news

China approval for TransThera’s Yochanra - The Pharma LetterThe Pharma Letter · Fri, 07 Aug 2026 19:24:48 GMT Japan's Ono Pharmaceutical Funds Fibrosis Discovery After Lilly's $99M Bet on Same Biotech - Tech TimesTech Times · Fri, 07 Aug 2026 17:47:39 GMT Mediar Therapeutics enters option deal with Ono Pharma - The Pharma LetterThe Pharma Letter · Fri, 07 Aug 2026 10:18:54 GMT Evotec and Odyssey Therapeutics enter AI-enabled drug discovery collaboration in autoimmune and inflammatory diseases - The Pharma LetterThe Pharma Letter · Fri, 07 Aug 2026 10:18:54 GMT Mediar and Ono to develop fibro-inflammatory treatments - Pharmaceutical TechnologyPharmaceutical Technology · Fri, 07 Aug 2026 08:48:19 GMT Mediar and Ono to Develop Novel Treatments Targeting Fibro-Inflammatory Diseases - Contract PharmaContract Pharma · Thu, 06 Aug 2026 20:17:24 GMT Mediar partners with Ono Pharma on fibro-inflammatory discovery - AllSciAllSci · Thu, 06 Aug 2026 16:25:44 GMT Mediar Therapeutics Enters into a Collaboration and Option Agreement with Ono Pharma to Develop Novel Treatments for Fibro-inflammatory Diseases - PR NewswirePR Newswire · Thu, 06 Aug 2026 11:00:00 GMT

Timeline

Fri, 07 Aug 2026 19:24:48 GMTChina approval for TransThera’s Yochanra - The Pharma Letter

Fri, 07 Aug 2026 17:47:39 GMTJapan's Ono Pharmaceutical Funds Fibrosis Discovery After Lilly's $99M Bet on Same Biotech - Tech Times

Fri, 07 Aug 2026 10:18:54 GMTMediar Therapeutics enters option deal with Ono Pharma - The Pharma Letter

Fri, 07 Aug 2026 10:18:54 GMTEvotec and Odyssey Therapeutics enter AI-enabled drug discovery collaboration in autoimmune and inflammatory diseases - The Pharma Letter

Fri, 07 Aug 2026 08:48:19 GMTMediar and Ono to develop fibro-inflammatory treatments - Pharmaceutical Technology

Thu, 06 Aug 2026 20:17:24 GMTMediar and Ono to Develop Novel Treatments Targeting Fibro-Inflammatory Diseases - Contract Pharma

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Ono Pharma7 live mentions The Pharma Letter5 live mentions Ono4 live mentions Develop Novel Treatments4 live mentions Fibro4 live mentions Mediar3 live mentions Collaboration3 live mentions China2 live mentions TransThera2 live mentions Ono Pharmaceutical Funds2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Mediar Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.